AMD Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

The global market for AMD drugs is primarily driven by the surge in demand for these drugs due to the increasing geriatric population; the rising number of novel product launches. An increase in age-related macular degeneration cases is also aiding the market growth. Various latest AMD drugs are being launched, and several pipelines and clinical trials or studies are taking place to contribute to the growth of the global AMD drugs market. For instance, in Aug 2022, Kodiak Sciences Inc. announced positive results from the phase 3 BEACON study of tarcocimab tedromer’s (KSI-301: tarcocimab), its new antibody biopolymer conjugate met the endpoints of non-inferior change in visual acuity at 24 weeks as compared to aflibercept in macular edema patients.